Unleashing unconventional antigens for cancer immunotherapy
The Enara Bio® purpose
Shining a light on Dark Antigen® and T-cell biology to enable people to live free from the shadow of cancer.
Our mission is to exploit previously uncharted genomic dark matter to develop cancer immunotherapies that deliver transformative benefit for broad patient populations.
To achieve our mission, we have built two innovative technology platforms:
EDAPT® pipeline that enables us to discover and validate a novel class of cancer-specific antigens derived from the genomic dark matter, which we call Dark Antigens.
EnTiCE® platform for optimizing proprietary bispecific T-cell engagers to deliver best-in-class treatments for solid tumors.
We are rapidly advancing our lead program to the clinic, a bispecific T-cell engager that targets a previously undiscovered antigen that we have named DARKFOX™.
Who we are
We are a diverse, experienced, and rapidly growing team driven by a common purpose and united by our shared values. The culture we have developed enables each of us to make an impact and deliver on our vision.
Featured news
-
Enara Bio enters 2026 with Dark Antigen licensing to Boehringer Ingelheim, appointment of Chief Medical Officer and plans to advance DARKFOX T-cell engager into First-in-Human studies
Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T-cell engagers for solid tumors, today announced that Boehringer Ingelheim has exercised its option to license multiple additional Dark Antigen targets discovered and validated through the collaboration with Enara.
-
Enara Bio’s DARKFOX Discovery Propels ENA101, the First Ever Bispecific T Cell Engager Targeting a Cancer-Specific Dark Antigen, into IND-Enabling Studies
Enara’s discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically actionable Dark Antigens and will be highlighted in an oral presentation at SITC 2025